Single photon emission computerized tomography (SPECT) in detecting neurodegeneration in Huntington's disease

Nuclear Medicine Communications

Volumn 23, Issue 1, 2002, Pages 13-18

  Reynolds, N C ^a   Hellman, R S ^a   Tikofsky, R S ^a   Prost, R W ^a   Mark, L P ^a   Elejalde, B R ^a   Lebel, R ^b   Hamsher, K S ^b   Swanson, S ^c   Benezra, E E ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Huntington's; Neurodegeneration; Perfusion; Striatum

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN PERFUSION; BRAIN SCINTISCANNING; CAUDATE NUCLEUS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; NERVE DEGENERATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; DNA; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; NERVE DEGENERATION; RADIOPHARMACEUTICALS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036189153     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200201000-00004     Document Type: Article

References (35)

1. Brandt J, Folstein SE, Folstein MF. Differential cognitive impairment in Alzheimer's disease and Huntington's disease. Ann Neurol 1988; 23: 555-561.
2. Ferranti RJ, Kowall NW, Beal MF, Richardson Jr. EP, Bird ED, Martin JB. Selective sparing of a class of striatal neurons in Huntington's disease. Science 1985; 230: 561-563.
3. Simmons JT, Pastakia B, Chase NT, Shults CW. Magnetic resonance imaging in Huntington's disease. Am J Neuroradiol 1986; 7: 25-28.
4. Starkstein SE, Brandt J, Blysma F, Peyser C, Folstein F, Folstein SE. Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study. Neuroradiology 1992; 34: 487-489.
5. Savoiardo M, Strada L, Oliva D, Girotti F, D'Incerti L. Abnormal MRI signal in the rigid form of Huntington's disease. J Neurol Neurosurg Psychiatr 1991; 54: 888-891.
6. Oliva D, Carella F, Savoiardo M, et al. Clinical and magnetic resonance features of the classic and akinetic-rigid variants of Huntington's disease. Arch Neurol 1993; 50: 17-19.
7. Kuhl DE, Phelps ME, Markham CH, Metter EJ, Riege WH, Winter J. Cerebral metabolism and atrophy in Huntington's disease by 18-FDG and computed tomographic scan. Ann Neurol 1982; 12: 425-434.
8. Hayden MR, Martin WR, Stoessl AJ, et al. Positron emission tomography in the early diagnosis of Huntington's disease. Neurology 1986; 36: 888-894.
9. Young AB, Penny JB, Starosta-Rubinstein S, et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann Neurol 1986; 20: 296-303.
10. Berent S, Giordani B, Lethinen S, et al. Positron emission tomographic scan investigations of Huntington's disease: cerebral metabolic correlates of cognitive function. Ann Neurol 1988; 23: 541-546.
11. Sokoloff L. Relationship among local functional activity, energy metabolism and blood flow in the central nervous system. Fed Proc 1981; 40: 2111-2316.
12. Raichle ME, Grubb RL, Gado MH, Eichling JO, Ter-Pogossian MM. Correlation between regional cerebral blood flow and oxidative metabolism. Arch Neurol 1976; 33: 523-526.
13. Lou HC, Edvinsson L, Mackenzie ET. The concept of coupling blood flow to brain function: revision required? Ann Neurol 1987; 22: 289-297.
14. Hasselbalch SG, Oberg G, Sorensen SA, et al. Reduced regional cerebral blood flow in Huntington's disease studied by SPECT. J Neurol Neurosurg Psychiatr 1992; 55: 1018-1023.
15. Sax DS, Powsner R, Kim A, et al. Evidence of cortical metabolic dysfunction in early Huntington's disease by single-photon-emission computed tomography. Mov Disord 1996; 11: 671-677.
16. Tanahashi N, Meyer JS, Ishikawa Y, et al. Cerebral blood flow and cognitive testing correlate in Huntington's disease. Arch Neurol 1985; 42: 1169-1175.
17. Nagel JS, Ichise M, Holman BL. The scintigraphic evaluation of Huntington's disease and other movement disorders using single photon emission computed tomography perfusion brain scans. Semin Nucl Med 1991; 21: 11-23.
18. Altrocchi PH, Brin M, Ferguson JH, et al. Assessment of brain SPECT. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996; 46: 278-285.
19. Taylor-Robinson SD, Weeks RA, Bryant DJ, et al. Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory? Mov Disord 1996; 11: 167-173.
20. Hoang TQ, Bluml S, Dubowitz DJ, et al. Quantitative proton-decoupled 31P-MRS and 1H-MRS in the evaluation of Huntington's and Parkinson's diseases. Neurology 1998; 50: 1033-1040.
21. Jenkins BG, Rosas HD, Chen Y-CI, et al. 1H-NMR spectroscopy studies of Huntington's disease. Neurology 1998; 50: 1357-1365.
22. Prost RW, Mark L, Mewisen M, Lis J. Detection of glutamate/glutamine resonances by 1H magnetic resonance spectroscopy at 0.5 Tesla. Magn Reson Med 1997; 37: 615-618.
23. Reynolds NC, Prost RW, Mark LR. Evidence for excitotoxicity: comparisons of proton magnetic resonance spectroscopy in Huntington's disease, idiopathic dystonia and progressive supra nuclear palsy. Mov Disord 1998; 13(S1): 42.
24. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
25. Hersch S, Jones R, Koroshetz W, Quaid K. The neurogenetics genie: testing for the Huntington's disease mutation. Neurology 1994; 44: 1369-1373.
26. Kremer B, Goldberg P, Andrew SE, et al. A worldwide study of the Huntington disease mutation, sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994; 330: 1401-1406.
27. Nance MA. Huntington disease - another chapter rewritten. Am J Hum Genet 1996; 59: 1-6.
28. Rubens AB, Tikofsky RS. Dementia. In van Heertum RL, Tikofsky RS, eds. Cerebral SPECT imaging. New York: Raven Press, 1995: 111-155.
29. Harris GJ, Pearlson GD, Peyser CE, et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann Neurol 1992; 31: 69-75.
30. Brücke T, Podreka I, Wenger S, Asenbaum S, Fertl E, Angelberger P. Dopamine D2 receptor measurement with SPECT in extrapyramidal disorders. Mov Disord 1992; 7(S1): 148.
31. Serrano C, Arroyo M, Silva F, Orduna E. Single photon emission computed tomography in neuroacanthocytosis. Mov Disord 1994; 9(S1): 117.
32. Rinne JO, Daniel SE, Scaravilli F, Pires M, Harding AE, Marsden CD. The neuropathological features of neuroacanthocytosis. Mov Disord 1994; 9: 297-304.
33. Delecluse F, Deleval J, Gérard JM, Michotte A, deBeyl DZ. Frontal impairment and hypoperfusion in neuroacanthocytosis. Arch Neurol 1991; 48: 232-234.
34. Warner JP, Barron LH, Brock DJH. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. Molec Cell Probes 1993; 7: 235-239.
35. Robertson SC, Mazzochi CA, Loftus CM. Effects of NMDA receptor activation on collateral cerebral blood flow. Soc Neurosci Abstr 1996; 22(1): 2.